Troglitazone
| Clinical data | |
|---|---|
| Trade names | Rezulin, Resulin, Romozin, Noscal |
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 16–34 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H27NO5S |
| Molar mass | 441.54 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 184 to 186 °C (363 to 367 °F) |
| |
| |
| (what is this?) (verify) | |
Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.
It was patented in 1983 and approved for medical use in 1997. It was subsequently withdrawn.